|
Nov 29
|
Harrow Completes Transfer of the TRIESENCE® New Drug Application
|
|
Jul 19
|
Why Shares of Harrow Health Are Jumping Wednesday
|
|
Jul 19
|
Harrow Prices $60 Million Public Offering of Common Stock
|
|
Jul 18
|
Harrow Acquires Santen’s Branded Ophthalmic Portfolio
|
|
Jul 18
|
Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance
|
|
Jul 18
|
Harrow Announces Proposed Public Offering of Common Stock
|
|
Jul 18
|
Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq
|